Literature DB >> 32628242

US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020.

Nadine Shehab1,2, Maribeth Lovegrove1, Daniel S Budnitz1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32628242      PMCID: PMC7536584          DOI: 10.1001/jamainternmed.2020.2594

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  2 in total

1.  Internet Searches for Unproven COVID-19 Therapies in the United States.

Authors:  Michael Liu; Theodore L Caputi; Mark Dredze; Aaron S Kesselheim; John W Ayers
Journal:  JAMA Intern Med       Date:  2020-08-01       Impact factor: 21.873

2.  Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment.

Authors:  Dan M Roden; Robert A Harrington; Athena Poppas; Andrea M Russo
Journal:  J Am Coll Cardiol       Date:  2020-04-10       Impact factor: 24.094

  2 in total
  3 in total

1.  Covid Media Misguidance: A Case Report Highlighting the Influence of Media on Patient Medication Decision Making.

Authors:  Shaylee Anderson; Joe Windscheffel; Karen Gunning
Journal:  Innov Pharm       Date:  2021-01-08

Review 2.  Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications.

Authors:  Rajnish Kumar; Anju Sharma; Janmejai Kumar Srivastava; Mohammed Haris Siddiqui; Md Sahab Uddin; Lotfi Aleya
Journal:  Environ Sci Pollut Res Int       Date:  2021-01-15       Impact factor: 4.223

3.  Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists.

Authors:  Antoine Bosquet; Comlan Affo; Ludovic Plaisance; Géraldine Poenou; Emmanuel Mortier; Isabelle Mahé
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.